Wednesday, February 8, 2023 Daily Archives

Personalis and Moderna team on mRNA cancer vax

by

Moderna will continue to use Personalis’ NeXT platform in its upcoming clinical trial of mRNA-4157/V940, an investigational personalized cancer vaccine.  The agreement, of which financial details have not been disclosed, sees the companies sign to continue to use Personalis’ NeXT platform to clinically evaluate mRNA-4157/V940, which is jointly developed by Moderna and Merck & Co. (known as MSD outside north America). Moderna transferred personalized cancer vaccine capabilities to its production facility in Norwood, Massachusetts in March 2019 and used the…

February 8, 2023

Vector BioMed launches CDMO following $15m funding

by

The CDMO says the funding will support delivery of rapid access to lentiviral vectors for pre-clinical development, clinical trials, and commercialization. Vector BioMed, a contract development manufacturing and organization (CDMO) focusing on the production of lentiviral vectors, has launched after its first financing round. “The first tranche was $7.5 million of $15 million,” a spokesperson for the start-up told BioProcess Insider. The funding aims to take the company’s vector-based medicinal concepts from the clinic and accelerate them towards commercialization. To…

February 8, 2023